NCT03439943 - Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease | Biotech Hunter

Enrollment

156

Participants

Timeline

Start Date

June 13, 2018

Primary Completion Date

April 15, 2021

Study Completion Date

April 15, 2021

Conditions

Parkinson Disease

Interventions

DRUG

Lixisenatide

Patients randomized in the Lixisenatide group will receive 10μg/day for 14 days and then 20μg/day administered by once-daily subcutaneous injections during 12 months. If patients are unable to tolerable the dose of 20μg/day, this dose can be reduced to 10μg/day

DRUG

placebo

Patients randomized in the placebo group will receive the corresponding placebo administered subcutaneously (once daily subcutaneous injection).

Trial Locations (20)

31000

CHU Toulouse, Toulouse

Unknown

University Hospital of Amiens, Amiens

University Hospital of Besancon, Besançon

University Hospital of Bordeaux, Bordeaux

University Hospital of Caen, Caen

University Hospital of Clermont-Ferrand, Clermont-Ferrand

Creteil- Henri Mondor Hospital, Créteil

University Hospital of Lille, Lille

University Hospital of Limoges, Limoges

University Hospital of Lyon, Lyon

University Hospital of Marseille, Marseille

University Hospital of Montpellier, Montpellier

University Hospital of Nancy, Nancy

University Hospital of Nantes, Nantes

University Hospital of Nice, Nice

Pitié Salpêtrière Hospital, Paris

University Hospital of Poitiers, Poitiers

University Hospital of Rennes, Rennes

University Hospital of Rouen, Rouen

University Hospital of Strasbourg, Strasbourg